Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Naoya Yamazaki(Tokyo National Hospital), Kenji Yokota(International Research Center for Japanese Studies), Manabu Fujimoto(Osaka Gakuin University), Hidefumi Wada(Yokohama City University), Takashi Inozume(Chiba University), Hisashi Uhara(Sapporo Medical University), Yoshio Kiyohara(Shizuoka Cancer Center), Tatsuya Takenouchi(Niigata Cancer Center Hospital), Kazuo Noguchi(MSD K.K. (Japan)), Hironobu Ihn(Kumamoto University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Takashi Shimamoto(University of Tsukuba), Hiroshi Furukawa(Aichi Medical University), Hiroshi Uchi(Kyushu University)
Cancer Chemotherapy and Pharmacology
March 11, 2017
10.1007/s00280-016-3237-x
Cited by 89

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses
|Immunity|2008|1.2k